Irish Cancer Society Clinical Trials Catalyst Award 2022

On this page:

Introduction

A key priority in the Irish Cancer Society strategy 2020-2025 is ensuring that Irish patients benefit from world-class cancer research and expertise. Central to this focus is fostering and cultivating clinical trial research to ensure that Irish cancer patients have access to excellent cancer treatment, research and leaders who will drive innovative, evidence-based improvements in patient care.

As part of this commitment, the Irish Cancer Society wishes to invite eligible research-active clinicians, primary care physicians, dentists, nurses, and allied health professionals in oncology-related fields to submit an application for the Clinical Trials Catalyst Award 2022.

The aims of the Award are to:

support activities necessary to evolve an existing clinical trial or the development of a clinical research project;
drive patient accrual in cancer clinical trials and studies;
support the career development of the clinical researcher through protected time specifically to focus on the initiation of a clinical trial.

The National Cancer Strategy 2017-2026 has called out the importance of cancer clinical trials as an integral and fundamental aspect of national cancer centres, and in line with this key unmet need, has set ambitious targets over the course of the strategy aimed at increasing patient participation to cancer clinical trials in Ireland. In recognition of this, it is expected that any clinical trial or study funded as part of this call should ultimately result in an increase in accrual on cancer clinical trials within the lifetime of the award.

Funding

Awards are available up to a maximum contribution of €40,000 towards a clinical trial or study over an 18-month funding period. Funding may be used to support clinical protected-time and/or project costs associated with facilitating a clinical trial.